NeOnc Technologies Holdings is trading at $3.54, up 8.59% per the supplied price context; no fresh company announcement explaining the November 2 move surfaced in the search.
- The reported FDA meeting for NEO212 was announced September 28 and is scheduled for November 17; it is prior context, not a new catalyst.
- Major U.S. indices were higher in the supplied market update, which may support a broader risk-on backdrop, but there is no evidence that it caused the stock’s gain.